Sustanon 250 - Zyvex Pharmaceuticals
Sustanon 250 - Four Esters, One Vial, More Management Work Than a Single Ester
Sustanon 250 is a testosterone blend containing four ester variants in a single 250 mg/ml solution: testosterone propionate (30 mg), testosterone phenylpropionate (60 mg), testosterone isocaproate (60 mg), and testosterone decanoate (100 mg). Developed by Organon as a TRT product intended to provide both rapid onset and long-acting coverage from a single injection, it became widely used in performance circles despite offering no pharmacological advantage over single-ester testosterone. The active hormone is identical to any other testosterone compound - the only variable is ester half-life, which determines how quickly the testosterone enters circulation and how long it persists.
The practical consequence of the four-ester design is that estrogen management is more difficult with Sustanon than with a single long-ester testosterone. Each ester releases testosterone at a different rate, producing overlapping peaks and troughs in serum testosterone levels. This makes it harder to dial in a stable aromatase inhibitor dose - blood testosterone (and therefore estrogen) is not rising and falling in a predictable single curve, but in multiple overlapping waves. For this reason, many experienced users prefer testosterone enanthate or cypionate for performance use and reserve Sustanon for its historical familiarity or regional availability.
About the Compound
Sustanon 250 was formulated by Organon in the 1970s as an androgen replacement therapy product. The rationale was sound for its era: by combining a fast-acting ester (propionate) with progressively longer esters (phenylpropionate, isocaproate, decanoate), a single injection could provide rapid testosterone elevation followed by sustained release over several weeks. In a clinical TRT context where patient compliance and injection frequency are concerns, this design has merit. In a performance context where injections are already administered multiple times per week, the blend offers nothing that a single long-ester testosterone cannot match with a simpler, more predictable pharmacokinetic profile.
The testosterone molecule itself is identical regardless of ester. Testosterone propionate, enanthate, cypionate, and decanoate all convert to the same active testosterone after esterase cleavage in the bloodstream. Anabolic and androgenic effects, aromatization rate per mg of free testosterone, HPTA suppression, and PCT requirements are functions of the free testosterone concentration, not the ester attached to it. What differs between testosterone compounds is the onset speed and duration of action determined by the ester. Sustanon 250 delivers all four in one vial.
Ester Composition
Each ml of Sustanon 250 contains the following four testosterone esters. The percentages reflect the contribution of each ester to the total 250 mg testosterone blend per ml.
| Ester | Amount per ml | Approximate Half-Life | Role in the Blend |
|---|---|---|---|
| Testosterone Propionate | 30 mg | 2-3 days | Fast onset - elevates testosterone within 24-48 hours of injection |
| Testosterone Phenylpropionate | 60 mg | 4-5 days | Short-medium bridge between propionate and the longer esters |
| Testosterone Isocaproate | 60 mg | 7-9 days | Medium-duration sustained release |
| Testosterone Decanoate | 100 mg | 14-15 days | Long-acting base; rate-limits PCT timing after the last injection |
The decanoate fraction (100 mg, the largest component) requires approximately 3 weeks to clear sufficiently for PCT drugs to work. Starting PCT too early while decanoate is still actively releasing testosterone will undermine the recovery process - the exogenous testosterone continues suppressing LH/FSH while you are attempting to restart natural production. The 3-week wait after the last Sustanon injection is not optional.
Dosing and Injection Schedule
Despite containing two long-acting esters (isocaproate and decanoate), Sustanon 250 requires twice-weekly injection for stable blood levels in a performance context. The reason is the propionate component. At 30 mg of propionate per ml, the fast-acting fraction clears within 2-3 days. If the full dose is administered once weekly, a significant drop in testosterone concentration occurs between injection day and the following week as the propionate and phenylpropionate fractions clear. This trough produces mood fluctuations, libido dips, and sub-optimal anabolic conditions mid-week. Twice-weekly injections (Monday and Thursday, or similar spacing) prevent this by continuously refreshing the fast-ester fractions.
| Experience Level | Weekly Dose | Injection Split | Cycle Length |
|---|---|---|---|
| First cycle / beginner | 400-500 mg/week | 200-250 mg Monday + Thursday | 10-12 weeks |
| Intermediate | 500-750 mg/week | 250-375 mg Monday + Thursday | 12-16 weeks |
| Advanced (with compounds) | 750-1000 mg/week | 375-500 mg Monday + Thursday | 12-16 weeks |
| TRT / cruise dose | 125-200 mg/week | 62.5-100 mg every 3.5 days | Ongoing |
Estrogen Management
Testosterone aromatizes to estradiol via the aromatase enzyme. At performance doses, estrogen management with an aromatase inhibitor (AI) is required. The challenge specific to Sustanon is that the four overlapping ester release curves produce less predictable estrogen fluctuations compared to a single-ester testosterone with a clean, consistent release profile. Users frequently report that the same AI dose that controlled estrogen well on testosterone enanthate provides inconsistent control on Sustanon - estrogen climbs higher at certain points in the week as multiple ester peaks overlap, and falls lower as short esters clear. The standard approach is to start with a conservative AI dose (anastrozole 0.5 mg twice weekly, or exemestane 12.5 mg every other day), test estradiol at 4-6 weeks, and adjust from there. Letrozole is too potent for routine Sustanon use and risks crashing estrogen.
Use Cases
| Goal | Protocol | Notes |
|---|---|---|
| First testosterone cycle | 500 mg/week, 10-12 weeks | 250 mg Monday and Thursday; AI on hand; bloodwork at weeks 4 and 8 |
| Bulking base compound | 500-750 mg/week alongside mass compounds | Paired with NPP, Deca, or Dianabol for off-season size; higher AI demand |
| Cutting test base | 400-500 mg/week | Maintains muscle and libido during deficit; pair with Masteron or Winstrol for hardening |
| TRT / hormone replacement | 125-200 mg/week | Provides stable testosterone levels; frequency every 3-4 days for even levels |
| Bridge between blasts | 200 mg/week cruise dose | Maintains suppression intentionally; used when PCT is not planned between cycles |
Side Effects
| Side Effect | Frequency / Background | Management |
|---|---|---|
| Estrogen elevation (water retention, gynecomastia risk) | Universal at performance doses; more variable than single-ester testosterone due to overlapping ester peaks | Aromatase inhibitor (anastrozole 0.5 mg 2x/week or exemestane 12.5 mg EOD); monitor estradiol via bloodwork |
| HPTA suppression | Complete at any meaningful dose; natural testosterone production shuts down within weeks | Expected during cycle; requires proper PCT (Nolvadex + Clomid) starting 3 weeks after last injection |
| Androgenic effects (acne, hair loss, oily skin) | Dose-dependent and genetically variable; highest risk in DHT-sensitive individuals | Keep doses conservative; finasteride for scalp if indicated; topical treatments for acne |
| Cardiovascular effects (hematocrit elevation, lipid changes) | Common at performance doses; hematocrit rises as red blood cell production increases | Regular blood donation or therapeutic phlebotomy; cardiovascular exercise; monitor hematocrit and lipids |
| Injection site reactions | Mild with oil-based compounds; propionate fraction may cause more discomfort than longer esters alone | Rotate injection sites; warm the oil before injecting; slow injection rate |
| Testicular atrophy | Occurs during any suppressive cycle; temporary and resolves after successful PCT | HCG 500 IU twice weekly during cycle prevents atrophy and makes PCT recovery faster |
The 3-week PCT wait after the last Sustanon 250 injection is set by the decanoate ester (100 mg, ~15-day half-life) - not by the shorter esters. Starting Nolvadex or Clomid while decanoate is still releasing meaningful testosterone wastes the SERM and delays recovery. Wait the full 3 weeks, then run a standard PCT: Nolvadex 40/40/20/20 mg per day for 4 weeks, optionally with Clomid 50/50/25/25 mg for the first two weeks. Bloodwork 4 weeks after completing PCT confirms whether natural testosterone has recovered.
Sustanon vs Testosterone Enanthate
| Feature | Sustanon 250 | Testosterone Enanthate |
|---|---|---|
| Ester composition | 4 esters (propionate, phenylpropionate, isocaproate, decanoate) | Single ester (enanthate, ~7-10 day half-life) |
| Blood level stability | Less predictable; overlapping multi-ester peaks | Smooth, predictable single-ester curve |
| Estrogen management | More difficult; variable estrogen peaks due to staggered ester release | Simpler; consistent AI dose works reliably |
| Injection frequency | Twice weekly required (propionate component) | Twice weekly recommended; once weekly functional at low doses |
| PCT start time | 3 weeks after last injection | 2 weeks after last injection |
| Anabolic / androgenic effect | Identical per mg of free testosterone | Identical per mg of free testosterone |
| Best suited for | Users who prefer a multi-ester blend; regional availability | Users who prefer simplicity and predictable estrogen control |
Frequently Asked Questions
What is Sustanon 250 and what esters does it contain?
Sustanon 250 is a testosterone blend containing four ester variants in a single 250 mg/ml oil-based solution. The four esters are: testosterone propionate (30 mg, half-life 2-3 days), testosterone phenylpropionate (60 mg, half-life 4-5 days), testosterone isocaproate (60 mg, half-life 7-9 days), and testosterone decanoate (100 mg, half-life 14-15 days). It was developed by Organon as a TRT product intended to provide rapid testosterone elevation from the propionate fraction followed by sustained release from the longer esters. The active hormone across all four fractions is identical - testosterone. The esters differ only in how quickly they are cleaved in the bloodstream, determining onset speed and duration.
Does Sustanon 250 work better than testosterone enanthate or cypionate?
No. There is no pharmacological advantage to the multi-ester blend for performance purposes. Testosterone is testosterone - the anabolic and androgenic effects, aromatization rate, and HPTA suppression are identical per mg of free testosterone regardless of whether it arrived in the bloodstream from a propionate ester or a decanoate ester. Sustanon 250 was designed as a clinical TRT product to reduce injection frequency for patients, not as a performance-enhancing formulation with superior properties. For performance use, single-ester testosterone enanthate or cypionate offers simpler pharmacokinetics and easier estrogen management. The belief that Sustanon is somehow more effective than single-ester testosterone at equivalent doses is a persistent myth with no scientific support.
Why does Sustanon 250 require twice-weekly injection if it contains long esters?
Because it also contains short esters. The propionate fraction (30 mg per ml) has a half-life of 2-3 days. If you inject Sustanon 250 only once per week, the propionate and phenylpropionate fractions clear mid-week, causing a significant drop in serum testosterone before the next injection. This produces the classic boom-bust pattern: testosterone peaks in the first 2-3 days after injection, then falls off sharply as the short esters clear while the isocaproate and decanoate fractions provide only partial coverage. The result is mood swings, libido dips, and suboptimal anabolic conditions mid-week. Twice-weekly injection (Monday and Thursday, or similar 3.5-day spacing) continuously refreshes all ester fractions and maintains stable blood levels throughout the week.
Is estrogen management harder with Sustanon than with a single-ester testosterone?
Yes - this is one of the most practically significant differences between Sustanon and single-ester testosterone for performance users. Each of the four esters releases testosterone at a different rate, producing overlapping peaks and troughs in serum testosterone that are more complex than the clean, single curve of testosterone enanthate or cypionate. When multiple ester peaks coincide, more testosterone is available for aromatization, causing estrogen spikes. When short esters clear between injections, estrogen drops. This variability makes it difficult to find a single stable AI dose that provides consistent estrogen control throughout the week. Users who switch from testosterone enanthate to Sustanon frequently report that the AI dose that worked well previously no longer provides the same control. Twice-weekly injection reduces but does not eliminate this variability.
What aromatase inhibitor should I use on a Sustanon 250 cycle?
The two most practical choices are anastrozole and exemestane. Anastrozole (Arimidex) at 0.5 mg twice weekly (on injection days) is a common starting point for a 500 mg/week Sustanon cycle. Exemestane (Aromasin) at 12.5 mg every other day is the alternative, with the advantage that it is a steroidal AI that does not rebound when discontinued (relevant at PCT time). Letrozole is too potent for routine Sustanon use at performance doses and risks crashing estrogen into a symptomatic low. The goal is not zero estrogen - it is optimal estrogen, typically in the 20-40 pg/ml range. Bloodwork at 4-6 weeks into the cycle is the only reliable way to confirm the AI dose is appropriate. Symptoms (water retention, mood changes, nipple sensitivity) are directional signals but not precise enough to replace testing.
When do I start PCT after a Sustanon 250 cycle?
Start PCT 3 weeks after the last Sustanon 250 injection. The timing is set by the decanoate ester (100 mg per ml, approximately 15-day half-life) - the largest fraction and the slowest to clear. Starting PCT before the decanoate has cleared means exogenous testosterone is still active in the bloodstream while you are attempting to restart natural LH/FSH production. The SERMs (Nolvadex, Clomid) cannot overcome ongoing testosterone suppression from active decanoate. The standard PCT protocol after the 3-week wait: Nolvadex 40/40/20/20 mg per day for 4 weeks, optionally with Clomid 50/50/25/25 mg per day for the first 2 weeks. Run bloodwork (total testosterone, LH, FSH) 4 weeks after completing PCT to confirm recovery.
What is the correct dose of Sustanon 250 for a first cycle?
500 mg per week is the standard recommendation for a first testosterone cycle, split into two injections of 250 mg (1 ml) on Monday and Thursday. This dose provides significant anabolic effect with a manageable side effect profile for a first-time user who does not yet know their personal estrogen response or androgenic sensitivity. A cycle length of 10-12 weeks allows enough time for the longer esters to fully saturate and produce consistent results before PCT. Have an aromatase inhibitor on hand before starting (not as an afterthought), and plan bloodwork at weeks 4 and 8 to assess hematocrit, estradiol, and lipids. Starting at 500 mg also leaves room to increase in future cycles once you understand how your body responds.
Can Sustanon 250 be used as a testosterone base alongside other compounds?
Yes, and this is one of its most common applications. Sustanon 250 at 400-500 mg per week provides a testosterone base that maintains physiological function (libido, mood, wellbeing, nitrogen retention) while other compounds drive the primary goals of the cycle. For bulking, it is commonly paired with NPP or Deca-Durabolin for mass and with Dianabol as a kickstart. For cutting, it is used at lower doses (400-500 mg/week) alongside Masteron or Winstrol for hardening effects. The key consideration when stacking is that each additional compound adds to the total androgenic and estrogenic load - the AI dose will need adjustment, and bloodwork becomes more important to catch hematocrit and lipid changes that multiple compounds can accelerate.
Related Products
